rewirebio.iobenchmarks
Evidence and investigation

Contested results

Where one study disagrees with what other studies report for the same models, and what we are doing to resolve each case.

These are automatic leads, not findings of error. Each release, a check compares how every study ranks the models it shares with other studies. It flags a study that reverses the order the others agree on, or whose gap to a shared reference model lies well outside theirs. Different tasks, populations or metrics often explain a flag.

A flag never hides a result. Flagged results stay in every table, page and download, marked Contested. A result is withheld only when a reviewer marks it disputed.

How the check works, and how each follow-up is recorded: discrepancies between studies.

In this release

  • 192open
  • 6settled
  • 7resolved
  • 3medium severity
  • 202low severity

Release 2026-11-21-c8bea25e5abb · 205 findings in all · rules version 5

Findings

Status: All · Open · Settled · Resolved

Severity: All · Medium · Low

State: All · Not yet reviewed · Under investigation · Explained · Confirmed error · Not a real disagreement

Showing findings that compare LIST-S2. All models

3 findings match, most severe first.

LIST-S2 and MetaLR: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MetaLR above LIST-S2 in 7 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks LIST-S2 above MetaLR in 4 of 5 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank LIST-S2 above MetaLR in 4 of their 13 comparisons and MetaLR higher in 8; 1 is a tie. Of those papers, Livesey and Marsh 2025 ranks MetaLR higher on its own (7 of 7).

Comparisons in which each paper scores LIST-S2 or MetaLR higher2 other papers: LIST-S2 higher in 4, MetaLR higher in 8, 1 tie.2 other papers4 LIST-S2 higher41 tie8 MetaLR higher8
LIST-S2 higherTieMetaLR higher
Compared
LIST-S2, MetaLR

Not reviewed yet.

LIST-S2 and M-CAP: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks M-CAP above LIST-S2 in 7 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks LIST-S2 above M-CAP in 5 of 6 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank LIST-S2 above M-CAP in 5 of their 13 comparisons and M-CAP higher in 8. Of those papers, Livesey and Marsh 2025 ranks M-CAP higher on its own (7 of 7).

Comparisons in which each paper scores LIST-S2 or M-CAP higher2 other papers: LIST-S2 higher in 5, M-CAP higher in 8, 0 ties.2 other papers5 LIST-S2 higher58 M-CAP higher8
LIST-S2 higherTieM-CAP higher
Compared
LIST-S2, M-CAP

Not reviewed yet.

LIST-S2 and MetaSVM: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MetaSVM above LIST-S2 in 7 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks LIST-S2 above MetaSVM in 3 of 4 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank LIST-S2 above MetaSVM in 3 of their 13 comparisons and MetaSVM higher in 8; 2 are ties. Of those papers, Livesey and Marsh 2025 ranks MetaSVM higher on its own (7 of 7).

Comparisons in which each paper scores LIST-S2 or MetaSVM higher2 other papers: LIST-S2 higher in 3, MetaSVM higher in 8, 2 ties.2 other papers3 LIST-S2 higher32 tie28 MetaSVM higher8
LIST-S2 higherTieMetaSVM higher
Compared
LIST-S2, MetaSVM

Not reviewed yet.